Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06409767

Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation.

Led by University Hospital, Angers · Updated on 2025-09-24

2224

Participants Needed

10

Research Sites

169 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Patients with hematologic malignancies requiring intensive chemotherapy are at risk for life-threatening complications. Organ failure may appear rapidly and delay in initiating life-sustaining interventions may result in increased mortality. This encourages great alertness although not all patients require close monitoring. It is therefore critical to identify which patients are the most at risk for clinical deterioration to consider increased surveillance in these patients. The benefit of early intensive care unit (ICU) admission, as soon as the first signs of organ dysfunction appear, must also be clarified. Such an intervention could increase survival of patients by close monitoring and early initiation of organ-specific interventions but could also be responsible for anxiety and increased use of ICU resources. Many teams have analyzed the impact of early warning systems (EWS) including vital signs to detect organ dysfunction early on. It has been shown that these EWS could positively impact survival in many medical fields (pre-hospital, medicine or surgery departments). A few retrospective studies have explored the impact of EWS in hematology, with overall good prediction for ICU admission and mortality. Until now, it has however not been formally demonstrated that early ICU admission, as soon as the first signs of organ dysfunction appear, could benefit patients with hematologic malignancies. A randomized controlled trial studying the impact of early intervention would clarify the role of such a strategy. In this study, the investigators will prospectively evaluate the implementation of the National Early Warning Score (NEWS), with systematic referral to the ICU in high-score patients, to improve the survival of patients receiving intensive chemotherapy in ten academic centers. This score is one of the most performant and most frequently used to predict organ failure. Its calculation only requires vital signs such as respiratory rate, peripheral oxygen saturation, need for oxygen therapy, body temperature, arterial pressure, heart rate, and level of consciousness. The investigators will therefore study the impact of ICU admission in patients with high NEWS in a randomized, controlled trial. A cluster randomization is planned in which the centers will be randomized between usual care (control group) and interventional care with transfer to the ICU in the event of a NEWS score ≥7 (interventional group). Each parameter used to calculate the NEWS will be collected at least three times a day by the attending nurse.

CONDITIONS

Official Title

Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation.

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult patient
  • Hospitalized in a protected hematology unit for induction therapy of acute myeloid leukemia, acute lymphoblastic leukemia, intensive chemotherapy with autologous or allogeneic hematopoietic cell transplantation
  • Expected hospital stay in hematology department of at least 7 days
  • Patient with social security
  • Signed informed consent form
Not Eligible

You will not qualify if you...

  • Decision to limit care with no transfer to ICU or no organ support initiation
  • Pregnant, parturient, or breastfeeding woman
  • Person deprived of liberty by judicial or administrative decision
  • Person under forced psychiatric care
  • Person under legal protection
  • Person unable to express consent
  • Hospitalization for Chimeric Antigenic Receptor (CAR) T-cell therapy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 10 locations

1

Centre Hospitalier Amiens-Picardie

Amiens, France, 80054

Actively Recruiting

2

Centre Hospitalier Universitaire d'Angers

Angers, France, 49933

Actively Recruiting

3

Centre Hospitalier Universitaire Besancon

Besançon, France, 25030

Actively Recruiting

4

Centre Hospitalier Universitaire Brest

Brest, France, 29609

Actively Recruiting

5

Centre Hospitalier universitaire Nancy

Nancy, France, 45011

Actively Recruiting

6

Centre Hospitalier Universitaire Nantes

Nantes, France, 44093

Actively Recruiting

7

Centre Hospitalier Universitaire poitiers

Poitiers, France, 86021

Actively Recruiting

8

centre Hospitalier Universitaire Saint etienne

Saint-Etienne, France, 42270

Actively Recruiting

9

centre Hospitalier Universitaire Strasbourg

Strasbourg, France, 67098

Not Yet Recruiting

10

centre Hospitalier Universitaire Tours

Tours, France, 37044

Actively Recruiting

Loading map...

Research Team

C

Corentin Orvain, MD PhD

CONTACT

A

Aurélie Hautefort

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here